John William Kauffman

Practice Details

• Firm Information
  Position

  Of Counsel

  Firm Name

  Duane Morris LLP
• Representative Cases & Transactions
  Cases

  Representative Matters: Represented Strata Skin Sciences, Inc. (SSKN: Nasdaq), a dermatology
  plastic surgery company, in a $17 million common stock financing led by Accelmed Growth Partners, an investment firm focused on medical technologies, which resulted in the appointment of a new CEO
  a restructuring of the Board of Directors.
  Represented Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) in a follow-on underwritten public offering of four million shares of common stock at a price of $9.50 per share, with expected gross proceeds of $38 million.
  Represented a publicly held insurance company in resolving a 10-year effort by a dissident stockholder seeking to acquire control of the company from its leadership. As part of the company's repurchase of the shares held by the dissident stockholder, he has agreed to refrain from any further attempt to control the company for 25 years.
  Represented MELA Sciences, Inc. (NASDAQ: MELA) in its purchase of the XTRAC
  VTRAC Dermatology business from PhotoMedex, Inc. for $42.5 million in cash
  the assumption of certain business-related liabilities
  the related financing with institutional investors consisting of a private placement of $42.5 million aggregate principal amount of senior secured notes
  convertible debentures
  warrants to purchase 3.0 million shares of common stock.
  Represented Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) in its public offering of 10.925 million shares of its common stock for total gross proceeds of $87.4 million.
  Represented Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) in an underwritten public offering, the gross proceeds of which were approximately $64 million.
  Represented Inovio Pharmaceuticals, Inc. with regard to a collaboration agreement,
  related securities law matters, with Roche to research, develop
  commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer (INO-5150)
  hepatitis B (INO-1800) as well as use of Inovio's CELLECTRA electroporation technology for delivery of the vaccines. The deal called for Inovio to receive an up-front payment of $10 million, as well as milestone payments of up to $412.5 million.
  Represented REIT in $90 million 144A convertible senior note offering.
  Formation of an insurance exchange in Pennsylvania for medical professional liability insurance coverage
  Advising public companies, boards of directors
  management regarding various aspects of corporate governance requirements under the Sarbanes-Oxley Act of 2002
  the rules of the New York Stock Exchange
  Nasdaq
  Private placements
  financings for early
  later stage companies
  Development of corporate takeover defenses, including stockholder rights plans